In parallel, the expression levels of fatty acid oxidising enzymes [AMPKα2, ACOX (Acyl-CoA Oxidase), MCAD (Medium-chain acyl-coenzyme A dehydrogenase), and VLCAD (Very Long Chain Acyl-CoA Dehydrogenase Deficiency)] increased in liver and skeletal muscle after ALS-L1023 treatment. The gene discussed is PRKAA2; the disease is hyperinsulinemic hypoglycemia, familial, 4.